Skip to content

Biohaven Pharmaceuticals

Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology.

Last updated September 11, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology. It states that it is advancing multiple early-to-late-stage drug development programs in these areas, building on its legacy of transforming the treatment of migraine with Nurtec ODT (rimegepant) and Zavzpret (zavegepant). The company describes combining internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital. Vlad Coric, M.D. is listed as Chairman & Chief Executive Officer.

History

Biohaven states that it is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology. It describes building upon a legacy of transforming the treatment of migraine with Nurtec ODT (rimegepant) and Zavzpret (zavegepant), and says it is advancing multiple early-to-late-stage drug development programs in immunology, obesity, neuroscience and oncology. The company states that it has combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital. According to its website, Vlad Coric, M.D. serves as Chairman & Chief Executive Officer.

Recent events

  • Nurtec ODT announced as primary partner of Rick Ware Racing entry[6]

    Reported:

    Biohaven announced that Nurtec ODT would be the primary partner for the No. 51 Rick Ware Racing entry throughout the 2021 NASCAR Cup Series season.

Sources7 sources

Cite this profile: Cite the canonical profile. /brand-wiki/biohaven-pharmaceuticals · Editorial policy · How profiles are compiled